NO20053341L - Hindring og behandling av Alzheimers sykdom. - Google Patents
Hindring og behandling av Alzheimers sykdom.Info
- Publication number
- NO20053341L NO20053341L NO20053341A NO20053341A NO20053341L NO 20053341 L NO20053341 L NO 20053341L NO 20053341 A NO20053341 A NO 20053341A NO 20053341 A NO20053341 A NO 20053341A NO 20053341 L NO20053341 L NO 20053341L
- Authority
- NO
- Norway
- Prior art keywords
- alzheimer
- disease
- prevention
- inhibitor
- treatment
- Prior art date
Links
- 208000024827 Alzheimer disease Diseases 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title abstract 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 abstract 1
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 abstract 1
- 229940123239 Cholesterol synthesis inhibitor Drugs 0.000 abstract 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 abstract 1
- 229940121773 Secretase inhibitor Drugs 0.000 abstract 1
- 239000003613 bile acid Substances 0.000 abstract 1
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 abstract 1
- 230000000968 intestinal effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000002483 medication Methods 0.000 abstract 1
- 238000011084 recovery Methods 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0215722A FR2848452B1 (fr) | 2002-12-12 | 2002-12-12 | Application des inhibiteurs de recapture intestinale des acides biliaires pour la prevention et le traitement de la maladie d'alzheimer |
| PCT/FR2003/003654 WO2004062652A1 (fr) | 2002-12-12 | 2003-12-10 | Application et traitement de la maladie d'alzheimer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20053341D0 NO20053341D0 (no) | 2005-07-08 |
| NO20053341L true NO20053341L (no) | 2005-09-07 |
Family
ID=32338722
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20053341A NO20053341L (no) | 2002-12-12 | 2005-07-08 | Hindring og behandling av Alzheimers sykdom. |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP1572174A1 (pl) |
| JP (1) | JP2006514063A (pl) |
| KR (1) | KR20050084250A (pl) |
| CN (1) | CN1726016A (pl) |
| AR (1) | AR042354A1 (pl) |
| AU (1) | AU2003296802A1 (pl) |
| BR (1) | BR0317280A (pl) |
| CA (1) | CA2507945A1 (pl) |
| CO (1) | CO5700712A2 (pl) |
| FR (1) | FR2848452B1 (pl) |
| HR (1) | HRP20050534A2 (pl) |
| MA (1) | MA27500A1 (pl) |
| MX (1) | MXPA05005556A (pl) |
| NO (1) | NO20053341L (pl) |
| NZ (1) | NZ540496A (pl) |
| PE (1) | PE20040770A1 (pl) |
| PL (1) | PL377110A1 (pl) |
| RS (1) | RS20050420A (pl) |
| RU (1) | RU2005121909A (pl) |
| TW (1) | TW200503707A (pl) |
| WO (1) | WO2004062652A1 (pl) |
| ZA (1) | ZA200504656B (pl) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7521481B2 (en) | 2003-02-27 | 2009-04-21 | Mclaurin Joanne | Methods of preventing, treating and diagnosing disorders of protein aggregation |
| WO2005049027A2 (en) | 2003-11-03 | 2005-06-02 | Probiodrug Ag | Combinations useful for the treatment of neuronal disorders |
| KR101099206B1 (ko) | 2004-02-05 | 2011-12-27 | 프로비오드룩 아게 | 신규한 글루타미닐 시클라제 저해제 |
| WO2006050359A2 (en) | 2004-11-02 | 2006-05-11 | Northwestern University | Pyridazine compounds and methods |
| WO2007127474A2 (en) | 2006-04-28 | 2007-11-08 | Northwestern University | Compositions and treatments using pyridazine compounds and cholinesterase inhibitors |
| TWI423802B (zh) * | 2007-05-22 | 2014-01-21 | Otsuka Pharma Co Ltd | 用於治療阿茲海默症之藥劑 |
| BR112014010223B8 (pt) | 2011-10-28 | 2021-02-23 | Lumena Pharmaceuticals Llc | uso de uma composição compreendendo inibidores de reciclagem de ácido de bílis e forma de dosagem pediátrica |
| KR102051031B1 (ko) * | 2011-10-28 | 2019-12-02 | 루메나 파마수티컬즈, 인코포레이티드 | 고담혈증 및 담즙 정체성 간 질환 치료용 담즙산 재순환 억제제 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2040996A1 (en) * | 1990-05-02 | 1991-11-03 | Robert L. Albright | Composition and method for controlling cholesterol |
| CA2104594C (en) * | 1991-02-22 | 2004-05-11 | Howard K. Shapiro | Use of pharmaceutical compounds in the treatment of symptoms of disorders related to neurological diseases and etiologically related symptomology |
| CA2258744A1 (en) * | 1996-06-27 | 1997-12-31 | G.D. Searle And Co. | Particles comprising amphiphilic copolymers, having a cross-linked shell domain and an interior core domain, useful for pharmaceutical and other applications |
| US5985936A (en) * | 1997-12-18 | 1999-11-16 | Forbes Medi-Tech, Inc. | Method of preventing and delaying onset of Alzheimer's disease and composition therefor |
| JP2002501887A (ja) * | 1998-01-28 | 2002-01-22 | ワーナー−ランバート・カンパニー | アルツハイマー病の治療方法 |
| US6080778A (en) * | 1998-03-23 | 2000-06-27 | Children's Medical Center Corporation | Methods for decreasing beta amyloid protein |
| DE19825804C2 (de) * | 1998-06-10 | 2000-08-24 | Aventis Pharma Gmbh | 1,4-Benzothiepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
| US6221897B1 (en) * | 1998-06-10 | 2001-04-24 | Aventis Pharma Deutschland Gmbh | Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use |
| DE19845405C2 (de) * | 1998-10-02 | 2000-07-13 | Aventis Pharma Gmbh | Arylsubstituierte Propanolaminderivate und deren Verwendung |
| WO2001056579A1 (en) * | 2000-02-04 | 2001-08-09 | Esperion Therapeutics Inc. | Methods for treating alzheimer's disease |
| US20020028826A1 (en) * | 2000-06-15 | 2002-03-07 | Robl Jeffrey A. | HMG-CoA reductase inhibitors and method |
| SE0104334D0 (sv) * | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Therapeutic agents |
| TWI329111B (en) * | 2002-05-24 | 2010-08-21 | X Ceptor Therapeutics Inc | Azepinoindole and pyridoindole derivatives as pharmaceutical agents |
-
2002
- 2002-12-12 FR FR0215722A patent/FR2848452B1/fr not_active Expired - Fee Related
-
2003
- 2003-12-10 KR KR1020057010595A patent/KR20050084250A/ko not_active Withdrawn
- 2003-12-10 WO PCT/FR2003/003654 patent/WO2004062652A1/fr not_active Ceased
- 2003-12-10 NZ NZ540496A patent/NZ540496A/en unknown
- 2003-12-10 HR HR20050534A patent/HRP20050534A2/xx not_active Application Discontinuation
- 2003-12-10 CN CNA2003801059727A patent/CN1726016A/zh active Pending
- 2003-12-10 PE PE2003001247A patent/PE20040770A1/es not_active Application Discontinuation
- 2003-12-10 JP JP2004566119A patent/JP2006514063A/ja not_active Abandoned
- 2003-12-10 MX MXPA05005556A patent/MXPA05005556A/es not_active Application Discontinuation
- 2003-12-10 AU AU2003296802A patent/AU2003296802A1/en not_active Abandoned
- 2003-12-10 RU RU2005121909/15A patent/RU2005121909A/ru not_active Application Discontinuation
- 2003-12-10 PL PL377110A patent/PL377110A1/pl not_active Application Discontinuation
- 2003-12-10 BR BR0317280-5A patent/BR0317280A/pt not_active IP Right Cessation
- 2003-12-10 RS YUP-2005/0420A patent/RS20050420A/sr unknown
- 2003-12-10 CA CA002507945A patent/CA2507945A1/fr not_active Abandoned
- 2003-12-10 AR ARP030104540A patent/AR042354A1/es not_active Application Discontinuation
- 2003-12-10 EP EP03815109A patent/EP1572174A1/fr not_active Withdrawn
- 2003-12-11 TW TW092134949A patent/TW200503707A/zh unknown
-
2005
- 2005-06-07 ZA ZA200504656A patent/ZA200504656B/en unknown
- 2005-06-09 CO CO05056010A patent/CO5700712A2/es not_active Application Discontinuation
- 2005-06-10 MA MA28329A patent/MA27500A1/fr unknown
- 2005-07-08 NO NO20053341A patent/NO20053341L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| MA27500A1 (fr) | 2005-08-01 |
| JP2006514063A (ja) | 2006-04-27 |
| CA2507945A1 (fr) | 2004-07-29 |
| WO2004062652A1 (fr) | 2004-07-29 |
| NZ540496A (en) | 2008-04-30 |
| AR042354A1 (es) | 2005-06-15 |
| FR2848452B1 (fr) | 2007-04-06 |
| FR2848452A1 (fr) | 2004-06-18 |
| CN1726016A (zh) | 2006-01-25 |
| MXPA05005556A (es) | 2005-07-26 |
| EP1572174A1 (fr) | 2005-09-14 |
| TW200503707A (en) | 2005-02-01 |
| BR0317280A (pt) | 2005-11-08 |
| NO20053341D0 (no) | 2005-07-08 |
| HRP20050534A2 (en) | 2006-11-30 |
| KR20050084250A (ko) | 2005-08-26 |
| PL377110A1 (pl) | 2006-01-23 |
| ZA200504656B (en) | 2006-08-30 |
| RU2005121909A (ru) | 2006-01-20 |
| PE20040770A1 (es) | 2004-12-10 |
| CO5700712A2 (es) | 2006-11-30 |
| AU2003296802A1 (en) | 2004-08-10 |
| RS20050420A (sr) | 2007-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT1509232E (pt) | Uma combinação de um antagonista de nmda e inibidores da acetilcolina esterase para o tratamento da doença de alzheimer | |
| NO20052760D0 (no) | Fremgangsmate for behandling av kreft og beslektede fremgangsmater. | |
| NO20044195L (no) | Biofosfoninsyrer for behandling og prevensjon av osteoprose | |
| NO20034590D0 (no) | Fremgangsmåter for behandling av vaskul¶r sykdom | |
| NO20055894L (no) | Fremgangsmater og blandinger for behandling av amyloidrelatertere sykdommer | |
| NO20050497L (no) | Anvendelse av CETP inhibitorer og eventuelt HMG COA reduserbare inhibitorer og/eller antihypertensiva | |
| DE60312017D1 (de) | Sulfonderivate zur hemmung von gamma-secretase | |
| NO20034549D0 (no) | Behandling av type 2 diabetes med inhibitorer av dipeptidyl peptidase IV | |
| NO20050607L (no) | Fremgangsmate og innretning for tildeling av CO | |
| NO20084362L (no) | Difenylazetidinon derivater inneholdende kolesterol absorbsjonsinhibitor aktivitet | |
| IS8071A (is) | Aðferð við meðhöndlun á hnútahersli, fitudreyra og tengdum ástands tegundum og lyfjafræðilegum samsetningum | |
| BRPI0413363A (pt) | formas de dosagem fornecendo liberação controlada de inibidores de proteìna de transferência de ésteres de colesterila e liberação imediata de inibidores de hmg-coa redutase | |
| WO2004010937A3 (en) | Method of treating cancer | |
| EA200500098A1 (ru) | Лекарственное средство и способ лечения патологического синдрома | |
| EA200400881A1 (ru) | Азаарилпиперазины | |
| AU2003231252A1 (en) | Methods and compositions for the treatment and prevention of intermittent claudication or alzheimer's disease | |
| WO2009027703A3 (en) | Identifying organ damage | |
| AR042354A1 (es) | Aplicacion de inhibidores de recaptura intestinal del acido biliar para la prevencion y el tratamiento de la enfermedad de alzheimer | |
| EA200702212A1 (ru) | Способ лечения или профилактики разрушения кости или остеопороза | |
| NO20033228L (no) | Anvendelse av IL-18 inhibitorer til behandling og/eller forhindring av hjertesykdom | |
| NO20061744L (no) | Terapeutisk behandling | |
| TW200635900A (en) | Chemical compound and its use | |
| NO20051664L (no) | Behandling av demens og Parkinsons sykdom | |
| WO2004087905A3 (en) | Protein tyrosine phosphatase and inhibitors thereof | |
| AU2003205174A1 (en) | Molecules for disease detection and treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |